These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6778531)

  • 21. Neurochemistry of the mucopolysaccharidoses: brain glycosaminoglycans in normals and four types of mucopolysaccharidoses.
    Constantopoulos G; McComb RD; Dekaban AS
    J Neurochem; 1976 May; 26(5):901-8. PubMed ID: 131847
    [No Abstract]   [Full Text] [Related]  

  • 22. Cystic fibrosis: distribution of mucopolysaccharides in fibroblast cultures.
    Danes BS; Bearn AG
    Biochem Biophys Res Commun; 1969 Sep; 36(6):919-24. PubMed ID: 4186555
    [No Abstract]   [Full Text] [Related]  

  • 23. Mobilization of heparan sulfate induced by immunostimulation in a patient with mucopolysaccharidosis IIIA.
    Zerial M; Florio C; Dolzani L; Moro L; Romeo D
    Biochem Med; 1984 Apr; 31(2):228-35. PubMed ID: 6232924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative estimation of lysosomal storage in mucopolysaccharidoses by electron microscopy analysis.
    Narajczyk M; Moskot M; Konieczna A
    Acta Biochim Pol; 2012; 59(4):693-6. PubMed ID: 23230565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical screening for mucopolysaccharidosis, mucolipidosis and oligosaccharidosis.
    Humbel R
    Helv Paediatr Acta; 1975 Jul; 30(2):191-200. PubMed ID: 807540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fluorometric titration in a method of metabolic cooperation in the differential diagnosis of mucopolysaccharidoses].
    Lebedeva TV; Odinokova ON; Krasnopol'skaia KD; Freĭdin MI
    Vopr Med Khim; 1988; 34(2):117-9. PubMed ID: 3135667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [You make the diagnosis. Mucopolysaccharidosis III A (Sanfillipo A disease)].
    Howanietz H; Widhalm K
    Padiatr Padol; 1987; 22(4):361-4. PubMed ID: 3125511
    [No Abstract]   [Full Text] [Related]  

  • 28. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses.
    Piotrowska E; Jakóbkiewicz-Banecka J; Barańska S; Tylki-Szymańska A; Czartoryska B; Wegrzyn A; Wegrzyn G
    Eur J Hum Genet; 2006 Jul; 14(7):846-52. PubMed ID: 16670689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Syndrome of the defective lysosome--the genetic mucopolysaccharidoses.
    Rennert OM
    Ann Clin Lab Sci; 1975; 5(5):355-62. PubMed ID: 810065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mucopolysaccharidosis (author's transl)].
    Orii T
    Rinsho Shinkeigaku; 1978 Dec; 18(12):758-63. PubMed ID: 155506
    [No Abstract]   [Full Text] [Related]  

  • 31. Biochemical and histopathological studies on patients with mucopolysaccharidoses, two of whom had been treated by fibroblast transplantation.
    Crow J; Gibbs DA; Cozens W; Spellacy E; Watts RW
    J Clin Pathol; 1983 Apr; 36(4):415-30. PubMed ID: 6403596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variations in urinary mucopolysaccharides after injection of fibroblasts into patients with mucopolysaccharidoses.
    Desjobert A; Larget-Piet L
    Clin Chem; 1987 Oct; 33(10):1879-82. PubMed ID: 2959400
    [No Abstract]   [Full Text] [Related]  

  • 33. Mucopolysaccharidoses and the blood-brain barrier.
    Sahin O; Thompson HP; Goodman GW; Li J; Urayama A
    Fluids Barriers CNS; 2022 Sep; 19(1):76. PubMed ID: 36117162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of D-glucuronic acid as reducing terminal of intracellular heparan sulfates.
    Klein U; von Figura K
    FEBS Lett; 1976 Dec; 71(2):266-8. PubMed ID: 137126
    [No Abstract]   [Full Text] [Related]  

  • 35. [Mucopolysaccharidosis].
    Orii T; Sukegawa K; Taga T
    Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):693-9. PubMed ID: 3152091
    [No Abstract]   [Full Text] [Related]  

  • 36. The mucopolysaccharidoses and mucolipidoses as model systems for the investigation of genetic disorders.
    Shapiro LJ
    Birth Defects Orig Artic Ser; 1981; 17(2):191-203. PubMed ID: 6461367
    [No Abstract]   [Full Text] [Related]  

  • 37. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis.
    Piotrowska E; Jakóbkiewicz-Banecka J; Tylki-Szymańska A; Czartoryska B; Wegrzyn A; Wegrzyn G
    Acta Paediatr; 2009 Apr; 98(4):743-9. PubMed ID: 19046346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Our experience with the mucopolysaccharidoses. Clinical contribution; 1st therapeutic results].
    Segni G; Ranno O; Scatena P; Valeri D
    Minerva Pediatr; 1975 Mar; 27(9):541-7. PubMed ID: 806781
    [No Abstract]   [Full Text] [Related]  

  • 39. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure.
    van der Lee JH; Morton J; Adams HR; Clarke L; Ebbink BJ; Escolar ML; Giugliani R; Harmatz P; Hogan M; Jones S; Kearney S; Muenzer J; Rust S; Semrud-Clikeman M; Wijburg FA; Yu ZF; Janzen D; Shapiro E
    Mol Genet Metab; 2017 Jun; 121(2):70-79. PubMed ID: 28501294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approach to the treatment of mucopolysaccharidoses by plasma and leucocyte transfusions.
    Blehová B; Pazoutová N; Milunicová A; Wiererová O
    Rev Czech Med; 1973; 19(2):111-5. PubMed ID: 4267973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.